Latest Conference Articles

February 17th 2023, 9:45pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

February 17th 2023, 9:15pm

Genitourinary Cancers Symposium (ASCO GU)

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.

February 17th 2023, 8:57pm

Transplantation and Cellular Therapy Meetings

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

February 17th 2023, 8:50pm

Transplantation and Cellular Therapy Meetings

The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.

February 17th 2023, 8:45pm

Genitourinary Cancers Symposium (ASCO GU)

Transurethral resection of bladder tumor followed by gemcitabine, cisplatin, and nivolumab led to stringent clinical complete responses in patients with muscle-invasive bladder cancer.

February 17th 2023, 8:10pm

Transplantation and Cellular Therapy Meetings

Early treatment with ruxolitinib led to high response rates in patients with steroid refractory acute graft-vs-host-disease, although benefits with ruxolitinib vs best available therapy were observed regardless of the timing of ruxolitinib administration.

February 17th 2023, 7:52pm

Transplantation and Cellular Therapy Meetings

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

February 17th 2023, 7:44pm

Transplantation and Cellular Therapy Meetings

Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.

February 17th 2023, 7:35pm

Transplantation and Cellular Therapy Meetings

CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.

February 17th 2023, 7:17pm

Transplantation and Cellular Therapy Meetings

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

February 17th 2023, 6:44pm

Transplantation and Cellular Therapy Meetings

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

February 17th 2023, 6:40pm

Transplantation and Cellular Therapy Meetings

Ruxolitinib induced clinically meaningful overall survival improvements by decreasing non-relapse mortality rates in patients with acute graft-vs-host-disease.

February 17th 2023, 6:12pm

Transplantation and Cellular Therapy Meetings

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

February 17th 2023, 6:05pm

Transplantation and Cellular Therapy Meetings

Timing of severe symptom onset is the only distinct difference between late and classic acute graft-vs-host disease, and long-term outcomes were similar between the two types of disease.

February 17th 2023, 5:50pm

Transplantation and Cellular Therapy Meetings

Patients with relapsed or refractory multiple myeloma treated with the CAR T-cell agent idecabtagene vicleucel had comparable efficacy and safety outcomes regardless of whether they had renal impairment, according to findings from a real-world study.

February 17th 2023, 4:45pm

Transplantation and Cellular Therapy Meetings

Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.

February 17th 2023, 1:29pm

Genitourinary Cancers Symposium (ASCO GU)

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

February 17th 2023, 12:38pm

Genitourinary Cancers Symposium (ASCO GU)

Andrea Necchi, MD, discusses updated analysis of cohort B in the phase 2 KEYNOTE-057 trial in non-muscle invasive bladder cancer.

February 16th 2023, 11:46pm

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years

February 16th 2023, 11:15pm

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.